| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Clinical Research Centers |
Neuroendocrine Unit (P.R., C.H., C.C., T.S., S.G.) and the General Clinical Research Center (G.N.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114; and Serono Laboratories, Inc. (J.G.), Norwell, Massachusetts 02061
Address all correspondence and requests for reprints to: Steven Grinspoon, M.D., Neuroendocrine Unit, Bulfinch 457B, Massachusetts General Hospital, Boston, Massachusetts 02114.
Human immunodeficiency virus (HIV) lipodystrophy (LIPO) is characterized by increased visceral adiposity, peripheral fat atrophy, dyslipidemia, and insulin resistance. GH concentrations are known to vary inversely with excess weight and body fat but have not been investigated in HIV lipodystrophy. Twenty-one subjects with HIV LIPO, 20 HIV-infected nonlipodystrophy subjects (NONLIPO), and 20 control (C) subjects were prospectively recruited for this study and compared.
Subjects in the three groups were all male, age-matched [median, 47 yr old (interquartile range, 37–50) LIPO; 41 (37–44) NONLIPO; and 43 (37–49) C], and body mass index-matched [median, 24.3 kg/m2 (interquartile range, 22.2–26.6) LIPO; 24.4 (23.3–25.9) NONLIPO; and 24.8 (22.7–26.1) C] (P > 0.05 for all comparisons). Visceral abdominal fat [16,124 mm2 (11,246–19,790) LIPO; 7,559 (5,134–11,201) NONLIPO; and 8,803 (6,165–11,623) C; P < 0.01 LIPO vs. NONLIPO and LIPO vs. C] and the ratio of visceral abdominal fat to sc abdominal fat [1.37 (0.71–2.44) LIPO vs. 0.57 (0.47–0.78) NONLIPO vs. 0.55 (0.41–0.71) C, P < 0.01 LIPO vs. NONLIPO and LIPO vs. C] were significantly increased in the LIPO subjects but were not significantly different between NONLIPO and C. The mean overnight GH concentration, determined from frequent sampling every 20 min (from 2000 h to 0800 h) was decreased in the LIPO subjects [0.38 µg/L (0.13–0.67) LIPO vs. 0.96 (0.53–1.30) NONLIPO vs. 0.81 (0.49–1.03) C, P < 0.05 LIPO vs. NONLIPO and LIPO vs. C] and not significantly different between NONLIPO and C. Pulse analysis demonstrated decreased baseline GH [0.08 µg/L (0.06–0.21) LIPO vs. 0.19 (0.10–0.32) NONLIPO vs. 0.17 (0.12–0.57) C, P < 0.05 LIPO vs. NONLIPO and LIPO vs. C] and GH peak amplitude [1.06 µg/L (0.46–1.94) LIPO vs. 2.47 (1.22–3.43) NONLIPO and 2.27 (1.36–4.25) C, P < 0.05 LIPO vs. NONLIPO and LIPO vs. C] in the LIPO subjects but no significant difference in pulse frequency. No significant differences were observed between NONLIPO and C for any GH parameter. Insulin-like growth factor-I was not different between the groups. Total body fat (r = -0.40, P = 0.01) and visceral fat (r = -0.58, P = 0.0001) correlated inversely with mean overnight GH concentrations in the HIV-infected patients. In a multivariate regression model, controlling for age, body mass index, body fat, and visceral fat, only visceral fat was a significant predictor of mean GH concentrations (P = 0.0036, r2 for model = 0.40).
These data demonstrate normal GH pulse frequency and insulin-like growth factor-I concentrations but reduced mean GH concentrations, basal GH concentrations, and GH pulse amplitude in patients with HIV lipodystrophy. Increased visceral adiposity is the strongest predictor of reduced GH concentrations in HIV lipodystrophy. Further studies are necessary to determine the clinical significance of reduced GH in patients with HIV lipodystrophy.
This article has been cited by other articles:
 |
|
 |
|
  R. J. Bedimo Body-Fat Abnormalities in Patients With HIV: Progress and Challenges J Int Assoc Physicians AIDS Care (Chic Ill), December 1, 2008; 7(6): 292 - 305. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Makimura, T. Stanley, D. Mun, S. M. You, and S. Grinspoon The Effects of Central Adiposity on Growth Hormone (GH) Response to GH-Releasing Hormone-Arginine Stimulation Testing in Men J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4254 - 4260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Mallewa, E. Wilkins, J. Vilar, M. Mallewa, D. Doran, D. Back, and M. Pirmohamed HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options J. Antimicrob. Chemother., October 1, 2008; 62(4): 648 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lo, S. M. You, B. Canavan, J. Liebau, G. Beltrani, P. Koutkia, L. Hemphill, H. Lee, and S. Grinspoon Low-Dose Physiological Growth Hormone in Patients With HIV and Abdominal Fat Accumulation: A Randomized Controlled Trial JAMA, August 6, 2008; 300(5): 509 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Brown Approach to the Human Immunodeficiency Virus-Infected Patient with Lipodystrophy J. Clin. Endocrinol. Metab., August 1, 2008; 93(8): 2937 - 2945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hakeem, I. W Campbell, and D. N. Bhattacharyya HIV-associated lipodystrophy - a new metabolic syndrome The British Journal of Diabetes & Vascular Disease, May 1, 2008; 8(3): 129 - 134. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Falasca, M. R. Manigrasso, D. Racciatti, P. Zingariello, M. Dalessandro, C. Ucciferri, P. Mancino, M. Marinopiccoli, C. Petrarca, P. Conti, et al. Associations between Hypertriglyceridemia and Serum Ghrelin, Adiponectin, and IL-18 Levels in HIV-infected Patients. Ann. Clin. Lab. Sci., December 1, 2006; 36(1): 59 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D'Amico, J. Shi, R. V Sekhar, F. Jahoor, K. J Ellis, K. Rehman, J. Willis, M. Maldonado, and A. Balasubramanyam Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome Am. J. Clinical Nutrition, July 1, 2006; 84(1): 204 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Lee, J. L. Chan, E. Sourlas, V. Raptopoulos, and C. S. Mantzoros Recombinant Methionyl Human Leptin Therapy in Replacement Doses Improves Insulin Resistance and Metabolic Profile in Patients with Lipoatrophy and Metabolic Syndrome Induced by the Highly Active Antiretroviral Therapy J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2605 - 2611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Luzi, E. Meneghini, S. Oggionni, G. Tambussi, L. Piceni-Sereni, and A. Lazzarin GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study Eur. J. Endocrinol., December 1, 2005; 153(6): 781 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vigano, S. Mora, P. Manzoni, L. Schneider, S. Beretta, M. Molinaro, B. di Natale, and P. Brambilla Effects of Recombinant Growth Hormone on Visceral Fat Accumulation: Pilot Study in Human Immunodeficiency Virus-Infected Adolescents J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4075 - 4080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Koutkia, B. Canavan, J. Breu, and S. Grinspoon Effects of Growth Hormone-Releasing Hormone on Bone Turnover in Human Immunodeficiency Virus-Infected Men with Fat Accumulation J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2154 - 2160. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Koutkia, B. Canavan, J. Breu, and S. Grinspoon Growth Hormone (GH) Responses to GH-Releasing Hormone-Arginine Testing in Human Immunodeficiency Virus Lipodystrophy J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Koutkia, B. Canavan, J. Breu, M. L. Johnson, and S. K. Grinspoon Nocturnal ghrelin pulsatility and response to growth hormone secretagogues in healthy men Am J Physiol Endocrinol Metab, September 1, 2004; 287(3): E506 - E512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Koutkia, B. Canavan, J. Breu, M. Torriani, J. Kissko, and S. Grinspoon Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy: A Randomized Controlled Trial JAMA, July 14, 2004; 292(2): 210 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Koutkia, B. Canavan, J. Breu, M. L Johnson, A. Depaoli, and S. K Grinspoon Relation of leptin pulse dynamics to fat distribution in HIV-infected patients Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1103 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Benavides and M. C Nahata Pharmacologic Therapy for HIV-Associated Lipodystrophy Ann. Pharmacother., March 1, 2004; 38(3): 448 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Koutkia, G. Meininger, B. Canavan, J. Breu, and S. Grinspoon Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E296 - E303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Torriani, C. Hadigan, M. E. Jensen, and S. Grinspoon Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome J Appl Physiol, September 1, 2003; 95(3): 1005 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Koutkia, B. Canavan, M. L. Johnson, A. DePaoli, and S. Grinspoon Characterization of leptin pulse dynamics and relationship to fat mass, growth hormone, cortisol, and insulin Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E372 - E379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. He, E. S. Engelson, J. B. Albu, S. B. Heymsfield, and D. P. Kotler Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy J Appl Physiol, May 1, 2003; 94(5): 2051 - 2057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Tong, J.-L. Sankale, C. M. Hadigan, G. Tan, E. S. Rosenberg, P. J. Kanki, S. K. Grinspoon, and G. S. Hotamisligil Regulation of Adiponectin in Human Immunodeficiency Virus-Infected Patients: Relationship to Body Composition and Metabolic Indices J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1559 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Meininger, C. Hadigan, P. Rietschel, and S. Grinspoon Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men Am. J. Clinical Nutrition, August 1, 2002; 76(2): 460 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Grinspoon and M. Gelato Editorial: The Rational Use of Growth Hormone in HIV-Infected Patients J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3478 - 3479. [Full Text] [PDF]
|
|
|
|
|
|
J. C. Lo, K. Mulligan, M. A. Noor, J.-M. Schwarz, R. A. Halvorsen, C. Grunfeld, and M. Schambelan The Effects of Recombinant Human Growth Hormone on Body Composition and Glucose Metabolism in HIV-Infected Patients with Fat Accumulation J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3480 - 3487. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
